Education
About Us
Working with TipRanks
Follow Us
Britannia Life Sciences Inc (TSE:BLAB)
:BLAB
BLAB Stock Chart & Stats
C$0.08
C$0.00(0.00%)
At close: 4:00 PM EST
C$0.08
C$0.00(0.00%)
Day’s Range― - ―
52-Week RangeC$0.05 - C$0.14
Previous CloseN/A
Volume35.00K
Average Volume (3M)73.07K
Market Cap
C$16.23M
Enterprise ValueC$17.81M
Total Cash (Recent Filing)C$861.63K
Total Debt (Recent Filing)C$2.44M
Price to Earnings (P/E)―
Beta-1.54
Next Earnings
Mar 04, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding162,254,330
10 Day Avg. Volume81,691
30 Day Avg. Volume73,070
Financial Highlights & Ratios
PEG Ratio-0.81
Price to Book (P/B)1.93
Price to Sales (P/S)32.95
P/FCF Ratio-4.65
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue GrowthSustained triple-digit revenue growth signals strong product-market fit and expanding commercial traction. Over a 2–6 month horizon this supports durable top-line momentum, greater scalability, and more leverage for R&D and partnerships, improving the company's ability to fund future innovation.
Improved Leverage ManagementAn improving debt-to-equity trend indicates management is addressing historical leverage, which strengthens balance sheet flexibility. Over months this reduces refinancing risk, lowers interest burden potential, and enhances capacity to make strategic investments or weather industry funding cycles.
Strong Unit EconomicsHigh gross margins and a positive TTM ROE imply attractive product economics and some realized shareholder returns at the operating level. If operating expense discipline continues, these structural strengths support long-term margin recovery and sustainable profitability potential.
Bears Say
Negative Net ProfitabilityPersistent negative net margins and volatile operating profits indicate core profitability issues. Over months this can constrain reinvestment, limit ability to scale commercial operations, and require ongoing external funding unless operating leverage or cost structure is meaningfully improved.
Negative Operating Cash FlowOngoing negative operating cash flow signals the business is not yet self-funding core operations, increasing reliance on financing or partnerships. Persisting shortfalls erode liquidity and can force dilutive capital raises or constrain growth investments over the medium term.
Low Equity Ratio / Financial InstabilityA low equity ratio and history of high leverage raise solvency concerns if revenue volatility persists. Structurally this limits resilience to shocks, increases refinancing and covenant risk, and reduces strategic optionality compared with peers with stronger capital structures.
Britannia Life Sciences Inc News
BLAB FAQ
What was Britannia Life Sciences Inc’s price range in the past 12 months?
Britannia Life Sciences Inc lowest stock price was C$0.05 and its highest was C$0.14 in the past 12 months.
What is Britannia Life Sciences Inc’s market cap?
Britannia Life Sciences Inc’s market cap is C$16.23M.
When is Britannia Life Sciences Inc’s upcoming earnings report date?
Britannia Life Sciences Inc’s upcoming earnings report date is Mar 04, 2026 which is in 12 days.
How were Britannia Life Sciences Inc’s earnings last quarter?
Britannia Life Sciences Inc released its earnings results on Dec 01, 2025. The company reported -C$0.002 earnings per share for the quarter, missing the consensus estimate of N/A by -C$0.002.
Is Britannia Life Sciences Inc overvalued?
According to Wall Street analysts Britannia Life Sciences Inc’s price is currently Overvalued.
Does Britannia Life Sciences Inc pay dividends?
Britannia Life Sciences Inc does not currently pay dividends.
What is Britannia Life Sciences Inc’s EPS estimate?
Britannia Life Sciences Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Britannia Life Sciences Inc have?
Britannia Life Sciences Inc has 162,254,330 shares outstanding.
What happened to Britannia Life Sciences Inc’s price movement after its last earnings report?
Britannia Life Sciences Inc reported an EPS of -C$0.002 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Britannia Life Sciences Inc?
Currently, no hedge funds are holding shares in TSE:BLAB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Britannia Life Sciences Inc
Britannia Life Sciences Inc. provides product testing, safety assessment, and compliance services to the cosmetics, nutraceutical, and consumer packaged goods industries in the United Kingdom and internationally. The company is based in Toronto, Canada.
Technical Analysis
Hemostemix
―
Innovotech
―
Sirona Biochem
―
Glow LifeTech
―
Telescope Innovations Corp
―